2025
Uric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial
Patel R, Kumskova M, Kodali H, Budnik I, Kuznetsov V, Jain A, Jha A, Thedens D, Dhanesha N, Sutariya B, Nagarkatti K, Lamb J, Kamat P, Shi Y, Avery B, Imai T, Jin X, Chauhan A, Boisserand L, Khan M, Dhandapani K, Sanganahalli B, Sansing L, Hess D, Koehler R, McCullough L, Aronowski J, Ayata C, Diniz M, Lyden P, Planas A, Chamorro A, Chauhan A, Leira E, Investigators O. Uric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial. Stroke 2025, 56: 965-973. PMID: 40091742, PMCID: PMC11932773, DOI: 10.1161/strokeaha.124.048748.Peer-Reviewed Original ResearchConceptsUA-treated animalsPrimary functional outcomeFunctional outcomesMiddle cerebral artery filament occlusionModified intention-to-treat populationIntention-to-treat populationUric acidHuman clinical trialsImprove functional outcomesStudy drugIntravenous salineEffects of UARelevant to patientsClinical trialsPrimary outcomeSaline controlsSecondary outcomesPreclinical trialsDay 2Survival rateDay 7Filament occlusionGroups of animalsComorbiditiesDiverse comorbidities
2024
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review
Leber A, Ramachandra R, Ceban F, Kwan A, Rhee T, Wu J, Cao B, Jawad M, Teopiz K, Ho R, Le G, Ramachandra D, McIntyre R. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review. Expert Opinion On Pharmacotherapy 2024, 25: 467-476. PMID: 38515004, DOI: 10.1080/14656566.2024.2334424.Peer-Reviewed Original ResearchPositive and Negative Syndrome ScalePANSS total score changeTotal score changeBaseline to week 5Randomized controlled trialsNegative Syndrome ScaleSchizophrenia spectrum disordersPlacebo groupScore changesSyndrome ScaleTreatment of adultsSpectrum disorderSchizophreniaXanomelineWeek 5Dry mouthClinical Trials RegistryTreatment avenuesPlaceboSide effectsPreclinical trialsTrials RegistryControlled trialsPRISMA guidelinesSystematic review
2023
A multi-laboratory preclinical trial in rodents to assess treatment candidates for acute ischemic stroke
Lyden P, Diniz M, Bosetti F, Lamb J, Nagarkatti K, Rogatko A, Kim S, Cabeen R, Koenig J, Akhter K, Arbab A, Avery B, Beatty H, Bibic A, Cao S, Simoes Braga Boisserand L, Chamorro A, Chauhan A, Diaz-Perez S, Dhandapani K, Dhanesha N, Goh A, Herman A, Hyder F, Imai T, Johnson C, Khan M, Kamat P, Karuppagounder S, Kumskova M, Mihailovic J, Mandeville J, Morais A, Patel R, Sanganahalli B, Smith C, Shi Y, Sutariya B, Thedens D, Qin T, Velazquez S, Aronowski J, Ayata C, Chauhan A, Leira E, Hess D, Koehler R, McCullough L, Sansing L. A multi-laboratory preclinical trial in rodents to assess treatment candidates for acute ischemic stroke. Science Translational Medicine 2023, 15: eadg8656. PMID: 37729432, DOI: 10.1126/scitranslmed.adg8656.Peer-Reviewed Original ResearchConceptsPreclinical assessmentFocal cerebral ischemic insultAcute ischemic strokeCerebral ischemic insultLarge clinical trialsDiet-induced obesityNew clinical interventionsIntravascular thrombectomyIschemic strokeStroke treatmentHypertensive ratsIschemic insultBlinded assessmentClinical trialsYoung miceTreatment candidatesExclusion criteriaAnimal modelsYoung ratsFutile interventionsPreclinical trialsClinical interventionsFutility boundariesMiceDisease areasEmbracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial
Morais A, Locascio J, Sansing L, Lamb J, Nagarkatti K, Imai T, van Leyen K, Aronowski J, Koenig J, Bosetti F, Lyden P, Ayata C, Bosetti F, Koenig J, Lyden P, Lamb J, Nagarkatti K, Hess D, Kamat P, Khan M, Dhandapani K, Arbab A, Siddiqui S, Smith C, Nisar M, Leira E, Chauhan A, Dhanesha N, Patel R, Kumskova M, Thedens D, Wang K, Ayata C, Morais A, Imai T, Qin T, Jin X, Erdogan T, Yu L, Mandeville J, Kimberly W, Whittier J, Lo E, Arai K, Van Leyen K, Sansing L, Hyder F, Mihailovic J, Sanganahalli B, Diaz-Perez S, Velazquez S, Beatty H, Johnson C, Herman A, Boisserand L, Immakavar E, Koehler R, Dawson T, Dawson V, Shi Y, Avery B, Lannon S, Bibic A, Akhter K, Karuppagounder S, Aronowski J, McCullough L, Obertas L, Goh A, Huang S, Chauhan A. Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial. Stroke 2023, 54: 620-631. PMID: 36601951, PMCID: PMC9870939, DOI: 10.1161/strokeaha.122.040638.Peer-Reviewed Original ResearchConceptsTotal anesthesia durationAnesthesia durationIndependent predictorsMultivariable analysisClinical trialsTransient focal cerebral ischemiaFocal cerebral ischemiaCerebral blood flowLaser Doppler flowCentralized randomizationModified intentionTreat populationExperimental strokeCerebral ischemiaDoppler flowRodent modelsMCAOBlood flowNetwork trialFlow dropPreclinical trialsMouse cohortsStudy designTrialsTrial onset
2020
Stem Cell Therapy for Stroke
Robert S, Matouk C. Stem Cell Therapy for Stroke. 2020, 331-345. DOI: 10.1007/978-3-030-56954-9_15.ChaptersTissue plasminogen activatorCell therapyIntravenous tissue plasminogen activatorSurvival of patientsPost-ischemic brainCause of disabilityDevastating neurological disorderEffectiveness of treatmentStem cell therapyMechanical thrombectomyAcute settingSafety profileFunctional outcomeBrain damageCurrent treatmentBlood flowAnimal modelsPromising treatmentNeurological disordersBrain vasculaturePreclinical trialsStrokeTherapyPreclinical researchPatients
2018
Extracorporeal Perfusion in Vascularized Composite Allotransplantation
Kueckelhaus M, Puscz F, Dermietzel A, Dadras M, Fischer S, Krezdorn N, Pomahac B, Hirsch T. Extracorporeal Perfusion in Vascularized Composite Allotransplantation. Annals Of Plastic Surgery 2018, 80: 669-678. PMID: 29746324, DOI: 10.1097/sap.0000000000001477.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationSolid organ transplantationIschemia timeMachine perfusionOrgan transplantationReconstructive surgeryComposite allotransplantationClinical solid organ transplantationMachine perfusion systemImmunosuppressive treatmentGraft immunogenicityBroad clinical applicationLifelong monitoringTherapeutic measuresPerfusion strategyClinical successSevere injuriesPerfusion solutionPreclinical trialsClinical settingPlastic surgeryPerfusionImmunogenicityPerfusion systemClinical application
2017
Rapamycin treatment dose‐dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell‐cycle‐associated CDK1/cyclin axis
Li A, Fan S, Xu Y, Meng J, Shen X, Mao J, Zhang L, Zhang X, Moeckel G, Wu D, Wu G, Liang C. Rapamycin treatment dose‐dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell‐cycle‐associated CDK1/cyclin axis. Journal Of Cellular And Molecular Medicine 2017, 21: 1619-1635. PMID: 28244683, PMCID: PMC5543471, DOI: 10.1111/jcmm.13091.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticCDC2 Protein KinaseCell CycleCyclinsDose-Response Relationship, DrugFemaleFounder EffectGene Expression RegulationHumansIntegrasesKidneyMaleMiceMice, TransgenicMicrofilament ProteinsPolycystic Kidney, Autosomal DominantPromoter Regions, GeneticSignal TransductionSirolimusTOR Serine-Threonine KinasesTRPP Cation ChannelsConceptsAutosomal dominant polycystic kidney diseaseEnd-stage renal diseaseMouse modelCyclin-dependent kinase 1Kidney/body weight ratioPreclinical trialsVivo preclinical resultsBody weight ratioCre transgenic miceHigh-dose rapamycinStandardized animal modelHuman autosomal dominant polycystic kidney diseaseRapamycin (mTOR) inhibitor rapamycinDominant polycystic kidney diseaseMonths of ageOrthologous mouse modelConditional knockout miceDose-dependent mannerPolycystic kidney diseaseAberrant epithelial cell proliferationEpithelial cell proliferationNew molecular targetsADPKD therapyRenal functionADPKD mouse model
2009
Endovascular Approaches to Acute Stroke, Part 1: Drugs, Devices, and Data
Nogueira R, Schwamm L, Hirsch J. Endovascular Approaches to Acute Stroke, Part 1: Drugs, Devices, and Data. American Journal Of Neuroradiology 2009, 30: 649-661. PMID: 19279271, PMCID: PMC7051752, DOI: 10.3174/ajnr.a1486.Peer-Reviewed Original ResearchConceptsRecombinant tissue plasminogen activatorIntravenous recombinant tissue plasminogen activatorLonger treatment windowsAcute stroke treatmentHigher recanalization ratesTissue plasminogen activatorPublic health concernMechanical revascularizationAcute strokeReperfusion techniquesEndovascular therapyStroke treatmentEndovascular approachRecanalization ratePharmacologic strategiesTreatment windowUS FoodDrug AdministrationWire disruptionTheoretic advantagesPreclinical trialsHealth concernPlasminogen activatorTherapyStroke
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply